Cubist Pharmaceuticals Inc. said Monday that executive vice president and chief operating officer Robert J. Perez has been named president and chief operating officer.
The Lexington-based biopharmaceutical company makes an intravenous antibiotic called Cubicin.
Perez will now oversee all commercial, manufacturing, business development, and information technology functions. In this capacity, he will have responsibility for overseeing Cubist’s international business expansion, the company said in a press release.
In other personnel news, the company said that Michael Tomsicek, currently vice president of corporate finance, has been named senior vice president and deputy chief financial officer.
In addition, Thomas Rollins has been appointed senior vice president of program and portfolio management.
Cubist recently unveiled plans to generate $2 billion in global annual revenue in 2017, driven largely by organic growth.